Recent Stage II-IV Ovarian Cancer News

Ovarian Cancer Clinical Trials: What, Where, Why

(July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with... Continue Reading


Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer

(December 20, 2016)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies... Continue Reading


Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer

(November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed,... Continue Reading


Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations

(October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy.... Continue Reading


Tesaro Provides Real Benefit to Ovarian Cancer Patients

(October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase... Continue Reading


FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer

(September 6, 2016)

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced... Continue Reading


SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment

(August 22, 2016)

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line... Continue Reading


Intraperitoneal Chemotherapy Underused in Ovarian Cancer

(September 28, 2015)

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer.... Continue Reading


Personalized Immunotherapy Delays Recurrence in Ovarian Cancer

(April 28, 2015)

A new immunotherapy known as Vigil™ may help delay the recurrence of advanced ovarian cancer. These findings were presented at the 2015 Annual Meeting on Women’s Cancer, March 28–31, in Chicago,... Continue Reading


Lynparza Approved in Advanced Ovarian Cancer

(December 29, 2014)

CancerConnect News: The U.S. Food and Drug Administration has granted accelerated approval to LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective... Continue Reading


Next Page »